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Abstract
Background: Adipose tissue is a source of multipotent adult stem cells and it has the ability to differentiate into
several types of cell lineages such as neuron cells, osteogenic cells and adipogenic cells. Several reports have
shown adipose-derived stem cells (ASCs) have the ability to undergo cardiomyogenesis. Studies have shown 5-
azacytidine can successfully drive stem cells such as bone marrow derived stem cells to differentiate into
cardiomyogenic cells. Therefore, in this study, we investigated the effect 5-azacytidine on the cardiogenic ability of
ASCs.
Methods: The cardiogenic potential of ASCs was analysed by studying the morphological changes after induction,
the changes in the cardiogenic genes expression i.e. GATA4, MLC-2v, MLC-2a, NKX2.5, b-MHC, a-MHC, Atrial
natriuretic peptide (ANP), Connexin 43, Cardiac Troponin C, Cardiac Troponin I and myocyte enhancer factor
(MEF2C) and the changes of embryonic stem cells genes expression at P5 and P10 using quantitative PCR.
Results: Our results showed that the induced ASCs did not show significant morphological difference compared
to the non-induced ASCs. While quantitative PCR data indicated that most cardiogenic genes and stemness genes
expression level decreased after induction at P5 and P10.
Conclusion: 5-azacytidine is insufficient for the cardiogenic induction of the ASCs.
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1. Background
Myocardial infarction results in the death of cardiomyo-
cytes and these cells cannot regenerate as they are term-
inally differentiated. Dead cardiomyocytes are normally
replaced with scar tissue. Human adipose derived stem
cells (ASCs) have been shown to have the ability to dif-
ferentiate into cardiomyocytes under appropriate stimuli.
Furthermore, adipose tissue can be found in abundance
and easily harvested, which made it an attractive alterna-
tive stem cell source especially for transplantation pur-
poses. Transplantation of cultured cells has been
proposed as a treatment for heart failure and these cells
need to be cultured and expanded for a long period to
achieve a sufficient number of cells. However, safety and
efficacy of long-term cultured cells have become a major
concern in stem cell based therapy. These issues also
need to be addressed to ensure the safety of patients
undergoing stem cell transplantation. The efficacy of
stem cells can be evaluated by differentiation into specific
cells such as cardiomyocytes. For differentiation, stem
cells need to be induced in appropriate conditions and
stimuli to have structural and functional differentiated
cells.
Investigators have used different methods to induce the
adipose derived stem cells to differentiate into cardio-
myocytes. Planat-Benard et al. (2004) showed that stro-
mal cells from adipose tissue can spontaneously
differentiate into cardiomyocytes after several days indi-
cated by contractile activity and myotube-like structures
using semi solid methylcellulose containing cytokines [1].
Gaustad et al. (2004) showed that adipose derived stem
cells can be differentiated into cardiomyocytes using the
extracts of rat cardiomyocytes, which was indicated by
the expression of cardiac specific markers [2]. However,
this could be due to the transient exposure to exogenous
factors that enable it to differentiate into cardiomyocytes
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rather than the true potential of the ASCs to differentiate
[3].
5-azacytidine is a DNA methylation agent. DNA methy-
lation is an important epigenetic mechanism, which has
been reported to be involved in gene expression, chro-
matic modification, × chromosome inactivation, genomic
imprinting and endogenic gene silencing [4]. DNA methy-
lation is also important in maintaining pluripotency and
self-renewal of stem cells. To maintain pluripotency, genes
are usually activated during hypomethylation and genes
that are associated with differentiation are repressed by
hypermethylation [5]. Several reports have shown that 5-
azacytidine can be used to induce stem cells from bone
marrow [6] and adipose tissue [7] to differentiate into car-
diomyocytes. 5-azacytidine has been shown to promote
myogenic differentiation of bone marrow stromal cells [8].
The ASCs pretreated with 5-azacytidine before transplan-
tation into the myocardial scar was more efficient in
preserving the cardiac function [9]. However, the use of
5-azacytidine for cardiogenic differentiation is still contro-
versial. Several investigators have shown rather contradic-
tory evidences regarding the use of 5-azacytidine for
cardiogenic potential. Zhang et al. (2007) reported that the
potential of bone marrow derived stem cells to differenti-
ate into cardiomyocytes was passage-restricted as only P4
showed the formation of myotubes that expressed cardiac
specific markers after being treated with 5-azacytidine [9].
On the other hand, Liu et al. (2003) reported that rat bone
marrow stromal cells cannot be induced to differentiate
into cardiomyogenic cells using 5-azacytidine unless they
were immortalised cells [10].
The underlying mechanism of 5-azacytidine in promot-
ing stem cell differentiation is still poorly understood. The
effect of 5-azacytidine on the stemness gene expression
levels are also important to be evaluated as they can give
an insight on the extent of the cardiogenic differentiation
potential of ASCs. Therefore, the aim of this study was to
investigate the effect of 5-azacytidine on the cardiogenic
potential and the stemness characteristic of in vitro ASCs
at P5 and P10.
2. Results
2.1) The Morphological Changes of Induced ASCs
The cardiogenic induction was carried out at P5 and P10.
The non-induced ASCs which were maintained in basal
medium served as a control (Figure 1). Figure 1A showed
the morphology of ASCs after 24 hours of culture. The
ASCs lengthened in morphology after 1 week of culture
(Figure 1B). While Figures 1C and 1D showed ASCs
morphology after 2 weeks and 3 weeks of culture, respec-
tively where they increased in density and lengthened to
connect with the adjoining cells. After 2 days of being
induced with cardiogenic medium cocktail containing 5-
azacytidine, the morphology of the cells seems to change
gradually (Figure 2A). The ASCs increased in size after 1
week of induction (Figure 2B). The ASCs increased in
density and lengthened to form stick-like morphology at
2 weeks of induction (Figure 2C). They then connected
with adjoining cells after 2 weeks to form myotube-like
structures (Figure 2D). The cell population increased in
density and formed a ball-like appearance after 2 weeks
of induction (Figure 2E) but there was no spontaneous
Figure 1 Morphology of non-induced ASCs in basal medium
which served as a control. A) The ASCs after 24 hours of culture
(50× Magnification). B) ASCs lengthened in morphology after 1
week of culture. C) and D) ASCs lengthened and increased in
density after 2 and 3 weeks of culture, respectively (Magnification
200×).
Figure 2 Morphology of ASCs after undergoing cardiogenic
differentiation using 5-azacytidine for 24 hours and
maintained with basal medium for 3 weeks. A) The ASCs after 24
hours of induction. B) The induced ASCs gradually increased in size
after 1 week of induction. C) The induced ASCs lengthened and
formed stick-like morphology at 2 weeks of induction. D) The
induced ASCs formed a myotube-like structure after 2 weeks of
induction. E) The ASCs formed a ball-like appearance after 2 weeks
of induction but there was no spontaneous beating even after 4
weeks of induction. (Magnification 200×)
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beating of the structure even after 4 weeks of induction
as reported by Rangappa et al. (2003). However, the fea-
tures of induced ASCs were similar to non-induced ASCs
after 3 weeks of induction.
2.2) The Cardiac Specific Gene Expression Levels of ASCs
Contrary to prior findings by other investigators, quan-
titative PCR analysis showed that most of the cardiac
specific genes of ASCs decreased in expression after
being induced in cardiogenic medium for 3 weeks.
GATA-4 (Figure 3A) showed a modest increase by 2
fold in expression after induction compared to before
induction at P5. However, at P10, the Gata-4 expres-
sion showed no significant changes after induction
compared to before induction. Nkx 2.5 (Figure 3B)
showed similar pattern of expression as Gata-4 after
induction. At P5, it showed a modest increase in
expression compared to before induction, which was
not expressed at all. At P10, Nkx2.5 showed no signifi-
cant changes in its expression after induction com-
pared to before induction.
MLC-2a (Figure 3C) expression level decreased signifi-
cantly (P < 0.05) by 4 fold after induction at P5. However,
no significant changes were recorded after induction at
P10. MLC-2v (Figure 3D) have similar pattern as MLC-
2a where it decreased significantly (P < 0.05) by 5 fold at
P5 but at P10, there was no significant changes after
induction. b-MHC (Figure 3E) showed no significant
changes in its expression level at P5 and P10 after induc-
tion. The a-MHC (Figure 3F) expression decreased sig-
nificantly (P < 0.05) in expression by 4 fold at P5 after
induction. At P10, no statistically significant difference
was recorded. ANP (Figure 3G) expression decreased sig-
nificantly (P < 0.05) after induction at P5 and P10 by 80
fold and 40 fold, respectively. While Connexin 43 showed
no significant difference in its expression at both P5 and
P10 (Figure 3H).
Cardiac Troponin I (TnIc) (Figure 3I) showed no sig-
nificant difference in its expression level after induction
at both P5 and P10. While Cardiac Troponin T (TnTc)
(Figure 4A) expression decreased significantly (P < 0.05)
after induction at P5 and P10 by approximately 30 fold
and 6 fold, respectively. MEF2C (Figure 4B) showed sig-
nificant (P < 0.05) decrease in expression at P5 by 2.5
fold after induction but no significant difference was
recorded for MEF2C at P10. The cardiac a-actin (Figure
Figure 3 The expression level of GATA-4, Nkx 2.5, MLC-2a, MLC-2v, b-MHC, a-MHC, ANP, Connexin 43 and TnIc of ASCs at P5 and P10
before and after induction using cardiogenic medium containing 5-azacytidine. MLC 2a, MLC-2v and a-MHC decreased significantly at
P5 after induction. ANP decreased significantly at both P5 and P10 after induction. * P < 0.05 relative to before induction by paired t-Test.
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4C) expression decreased significantly (P < 0.05) by 40
fold at P5 and by 2 fold at P10 after induction. Desmin
(Figure 4D) also decreased significantly (P < 0.05) by
approximately 20 fold at both P5 and P10.
2.3) The Stemness Genes Expression Levels of ASCs
Quantitative PCR analysis on the stemness genes showed
that Sox2 (Figure 5A) decreased significantly (P < 0.05) by
2 fold at P5 but no significant changes were recorded at
P10. FGF4 (Figure 5B) decreased significantly (P < 0.05) by
6 fold after induction at P5 but no significant changes was
recorded at P10. Nanog3 (Figure 5C) also decreased signif-
icantly (P < 0.05) by 3 fold at P5 after induction and no
significant changes was recorded at P10. Oct4 (Figure 5D)
showed no significant changes in its expression at both P5
and P10.
3. Discussion
The ability of 5-azacytidine to induce cardiogenic differ-
entiation in stem cells or progenitor cells has been docu-
mented by other investigators especially using bone
marrow derived stem cells. Makino et al. (1999) has
successfully differentiated immortalised murine bone
marrow stromal cells into cardiomyogenic cells using 5-
azacytidine [11]. Xu et al. (2004) also showed that
mesenchymal stem cells derived from adult human bone
marrow can differentiate into cells with cardiomyocyte
phenotype [6]. Rangappa et al. (2003) reported that
mesencyhmal stem cells from adipose tissue of New Zeal-
and white rabbits can be differentiated into cardiomyo-
cytes and these transformed cells started to beat
spontaneously at 3 weeks after being treated with 5-aza-
cytidine [7]. While Burlacu et al. (2007) reported that 5-
azacytidine promotes rather than induces the myogenic
differentiation of bone marrow progenitor cells as it
enhanced the appearance of myogenic markers [8].
In contrast, our data showed that ASCs did not differ-
entiate into cardiomyocytes even after 4 weeks of induc-
tion. In the present study, we used the same method
described by Rangappa et al. (2003) with slight modifica-
tion where we induced the ASCs using the cardiogenic
medium cocktail containing 5-azacytidine (10 uM) for 24
hours and the cell culture was then maintained in normal
basal medium for 3 weeks. According to Rangappa et al.
Figure 4 The expression level of TnTc, MEF2C, a-actin and desmin of ASCs at P5 and P10 before and after induction using
cardiogenic medium containing 5-azacytidine. TnTc, a-actin and desmin decreased significantly at both P5 and P10 after induction. MEF2C
decreased significantly at P5 after induction. * P < 0.05 relative to before induction by paired t-Test.
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(2003), 24 hour incubation period using 5-azacytidine
was the most effective [7]. However, the phenotype of
cardiogenic cells and the conversion of ASCs into beat-
ing-cardiomyocytes as reported by Rangappa et al. (2003)
were not observed in the present study. Morphologically,
the only evident difference between induced and non-
induced ASCS is the formation of the ball-like structure.
The formation of myotube-like structure and the appear-
ance of ball-like structure after 3 weeks of induction in
the present study could be due to the post confluent
state of the induced ASCs. Similar features were also
observed in non-induced ASCs. In the present study, 5-
azacytidine may promote cell proliferation and viability
instead of differentiation into cardiomyocytes.
To analyse the molecular changes during cardiogenic
induction of ASCs by 5-azacytidine, we have studied a
panel of cardiac specific and non-cardiac specific gene
expression levels. Data from quantitative PCR showed
that most cardiogenic genes expression levels decreased
after induction at P5 and P10. In cardiogenesis, GATA-4,
Nkx2.5 and MEF2C were known as key regulator in car-
diac development (Planat-Bernard et al, 2004). The car-
diac transcription factors GATA-4 and Nkx 2.5 showed a
modest increase in expression at P5 but not at P10.
While MEF2C decreased at P5 and P10 after induction.
Similar effect was observed for atrial myosin light chain
(MLC-2a) and ventricular myosin light chain (MLC-2v),
which were found in atrial and ventricular respectively
were known as structural genes in cardiomyogenesis [1].
Other cardiogenic genes such as cardiac beta-myosin
heavy chain (b-MHC) and cardiac alpha-myosin heavy
chain (a-MHC) also known as cardiac structural genes
decreased at P5 and P10. They are mostly located in the
ventricles of the heart and involved in the early stage of
cardiogenesis in embryonic development [12]. Connexin
43 (Cx43) is the principal connexin isoform in the mouse
ventricle also decreased in expression. Cx43 provides
electrical coupling between cells [13]. Atrial natriuretic
peptide (ANP) is a secretion product, which is involved
in the later stage of cardiac development [1] decreased at
P5 and P10 after induction. Cardiac Troponin I (TnIc)
and Cardiac Troponin T (TnTc) were also structural
genes showed no significant changes in expression after
induction compared to before induction. Cardiac a-actin
and desmin [14], which was found mainly in smooth
muscle also decreased after induction at P5 and P10.
Figure 5 Embryonic stem cells gene (Stemness genes) expression levels of ASCs before and after induction using cardiogenic medium
containing 5-azacytidine. Most stemness genes decreased significantly (P < 0.05) after induction at P5. * P < 0.05 relative to before induction
by paired t-Test.
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This result showed that the cardiogenic medium contain-
ing 5-azacytidine used in this study is not sufficient to
increase the expression of cardiac specific genes in ASCs.
In the present study, we speculate that 5-azacytidine
alone may not be sufficient to support the cells to differ-
entiate into cardiomyocytes. Similar result was reported
by Lee et al (2009) who demonstrated that 5-azacytidine
alone cannot induce the ASCs to differentiate into cardi-
omyocytes especially at the early stages of cardiomyo-
genic [3]. A study by Martin-Rendon et al. (2008) also
showed that 5-azacytidine-treated MSCs derived from
umbilical cord, cord blood and bone marrow did not
generate cardiomyocytes in vitro [15]. Although 5-azacy-
tidine has been shown to induce cardiac-like phenotypes
in MSCs derived from bone marrow by activating a num-
ber of genes, its effect may not be specific [15]. The use
of growth factors and cytokines may be needed to induce
cardiomyogenic differentiation as shown by Planat-Bar-
nard et al. (2004) [1]. In this study, we have added basic
fibroblast growth factor (bFGF) in the induction medium
but it did not have any effect on the cardiogenic potential
of ASCs. The bFGF may only support the cells prolifera-
tion and viability of ASCs in vitro instead of the cells dif-
ferentiation mechanism. Data from Rosca and Burlacu
(2011) showed that treatment with 5-azacytidine may
promote subsequent cardiac differentiation but it is
dependent on finding the adequate conditions for cardio-
myogenic differentiation [16]. Correct concentration of
5-azacytidine coupled with the use of growth factors and
cytokines may be able to create an adequate conditions
for cardiomyogenic differentiation.
To evaluate the efficiency of ASCs differentiation during
cardiogenic induction, we have also analysed the embryo-
nic stem cell gene expression levels i.e. Nanog3, Sox2,
Oct4 and FGF4 after cardiogenic induction. These genes
showed a significant decrease at P5 but no significant
changes were recorded at P10. While Oct4 showed no sig-
nificant changes at both passage. These genes play an
important role in maintenance and differentiation of
embryonic stem cells, and the levels and activity of these
transcription factors are indicators of embryonic stem
cells pluripotent or differentiation status [17]. These genes
also can be used to determine the stemness properties of
adult stem cells such as ASCs [18]. Tay et al. (2008)
reported that attenuation of Nanog3, Oct4 and Sox2 pro-
motes the differentiation of embryonic stem cells [19]. In
the present study, the decrease of expression levels of
Nanog3, FGF4, and Sox2 indicates that there may be a dif-
ferentiation activity happening at P5. Sox2 was reported to
reduce during differentiation from mesodermal to hema-
topoietic progenitor cells [20]. The type of cell differentia-
tion that may happen in the present study is still
uncertain. Further investigation is needed to elucidate the
differentiation mechanism in MSCs treated with 5-
azacytidine because 5-azacytidine has been shown to
induce osteogenesis [21], adipogenesis and chondrogenesis
[16] in bone marrow derived stem cells. While at P10, 5-
azacytidine did not affect the embryonic stem cells gene
expression levels in the inducted ASCs.
4. Conclusion
In conclusion, 5-azacytidine is not effective on the cardi-
ogenesis of ASCs. Further investigation is needed to elu-
cidate adequate conditions to differentiate the ASCs
into mature cardiogenic cells.
5. Materials and Methods
5.1) Isolation of ASCs From Adipose Tissue
Approval to conduct this research was obtained from the
Research Committee of Universiti Kebangsaan Malaysia
Medical Centre (UKMMC) (Approval No: 02-01-02-
SF0290). The ASCs were harvested from lipoaspirate tis-
sue, which was obtained from 6 consented patients (40-60
years of age) undergoing intraoperative suction lipectomy
at the Subang Jaya Medical Centre, Malaysia. The lipoaspi-
rate tissue was digested in 0.3% Collagenase Type I solu-
tion (Sigma-Aldrich, St Louise, MO) for 2 hours at 37°C.
The isolated cells (P0; approximately 1,000 adherent cells)
were then cultured in basal medium containing Dulbecco’s
Modified Eagle Medium (DMEM)/Ham F12 medium sup-
plemented with 10% fetal bovine serum (FBS) (Gibco), 1%
antibiotic-antimycotic (Gibco), 1% glutamax (Gibco) and
1% vitamin C (Sigma-Aldrich, St Louise, MO). The ASCs
were incubated and maintained at 37°C with 5% carbon
dioxide with medium changed every 3 days. The ASCs
were grown from the initial plating and harvested using
0.125% trypsin-EDTA (Gibco) at P5 and P10.
5.2) Cardiogenic Differentiation of ASCs and
Morphological Evaluation
The cardiogenic differentiation capability of cultured
ASCs at P5 and P10 was tested using medium contain-
ing an equal volume Ham’s F12 medium and Dulbecco’s
Modified Eagle Medium (F12:DMEM) (Gibco Invitro-
gen, USA) supplemented with 10% (v/v) fetal bovine
serum (Gibco Invitrogen), 5% (v/v) human serum, 1%
(v/v) antibiotic antimycotic (Gibco Invitrogen), 1% (v/v)
glutamax (Gibco Invitrogen), and 1% (v/v) vitamin C
(Sigma, St Louis, MO), 10 uM 5-azacytidine (Sigma), 5
uL of 10 ug/L of bFGF (Peprotec, USA) and 5 uL of
0.25 mg/ml amphotericin (Sigma).
Cells were seeded at 10000 cells/cm2 in a culture flask
with 25 cm2 surface area (Orange Scientific, Belgium)
and maintained in 5% CO2 incubator at 37°C under 95%
humidity. After 24 hours of induction using cardiogenic
medium, the cell cultures were maintained in normal
basal medium (An equal volume Ham’s F12 medium
and Dulbecco’s Modified Eagle Medium (Gibco
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Invitrogen) was supplemented with 10% (v/v) fetal
bovine serum (Gibco Invitrogen), 5% (v/v) human
serum, 1% (v/v) antibiotic antimycotic (Gibco Invitro-
gen), 1% (v/v) glutamax (Gibco Invitrogen), and 1% (v/v)
vitamin C (Sigma) for 3 weeks. The medium was chan-
ged every 3 days. Cells were examined everyday by
using inverted phase contrast microscope for cells
growth and morphological changes. Photographs were
taken to record the changes in cell morphology.
5.3) RNA Extraction
Total RNA was extracted from the non-induced and
induced ASCs cultured at P5 and P10. The RNA was
homogenised and extracted using TRI reagent (Molecu-
lar Research Center, Cincinati, OH). Chloroform was
used for phase separation of the sample. Total RNA
from the sample was precipitated by using absolute iso-
propanol (Sigma) and polyacryl carrier (Molecular
Research Center) was added to the RNA which, cause
the sedimentation of the RNA extract. The RNA extract
was then centrifuged at 12000 rpm for 8 min at 4°C.
75% Ethanol was used to wash the extract and dried for
20 min. RNase and DNase free distilled water (Gibco
Invitrogen) was used to solubilise the RNA extract.
5.4) cDNA Synthesis
The solubilised RNA extracts from ASCs cultured at P5
and P10 were used to synthesise cDNA by using Super-
Script III First-Strand Synthesis SuperMix kit for two-
step quantitative RT-PCR (Invitrogen). The synthesis
was carried out according to the optimised protocol
recommended by the manufacturer. The protocol condi-
tions were 10 min at 23°C, 60 min at 42°C and 10 min
at 94°C. The synthesised cDNA was used to perform
Real time PCR to evaluate the expression level of the
stemness genes.
5.5) Cardiogenic and Stemness Gene Expression Analysis
Using Quantitative PCR
The non-induced and induced ASCs cultured at P5 and
P10 were analysed for cardiogenic genes expression i.e.
Gata4, MLC-2v, MLC-2a, Nkx2.5, b-MHC, a-MHC, Atrial
natriuretic peptide (ANP), Connexin 43, Cardiac Troponin
C (TnIc), Cardiac Troponin I (TnTc) and myocyte enhan-
cer factor (MEF2C) (Table 1) and stemness genes expres-
sion level i.e. Sox-2, Nanog3, FGF4 and Oct-4 (Table 2).
GAPDH was used as the housekeeping gene. Primers for
each gene were designed by using Primer 3 software based
on the published GeneBank database sequences. The PCR
Table 1 Description of cardiogenic gene primers used in quantitative PCR
Gene Accession No Primer 5’ 3’ PCR product size
(bp)
GATA-4 NM_002052 R 5’-CTCCTACTCCAGCCCCTACC-3’ 207
F 5’-GTGGACATAGCCCCACAGTT-3’
MLC-2a NM_021223 R 5’-GCAGACCTGAGGGAGACCTAC-3’ 135
F 5’-ATTGAGCTTCTCCCCAAAGAG-3’
MLC-2v NM_000432 R 5’-ACAGGGATGGCTTCATTGAC-3’ 192
F 5’-ATGCGTTGAGAATGGTTTCC-3’
Nkx2.5 NM_004387 R 5’-GAGAAGACAGAGGCGGACAA-3’ 187
F 5’-AGATCTTGACCTGCGTGGAC-3’
b-MHC NM_000257 R 5’-TGATCTGGAGCTGACACTGG-3’ 196
F 5’-CAGGGTGTTGACCTTGTCCT-3’
a-MHC NM_002471 R 5’-CCACCCAAGTTCGACAAGAT-3’ 127
F 5’-CACAGAAGAGGCCCGAGTAG-3’
ANP NM_000906 R 5’-GCATTGAGCTGACACGAAAA-3’ 219
F 5’-CCTTGACGATGTCATTGGTG-3’
Connexin 43 NM_000165 R 5’-GGACATGCACTTGAAGCAGA-3’ 103
F 5’-GATGATGTAGGTTCGAAGCA-3’
TnIc NM_000363 R 5’-CTCCAACTACCGCGCTTATG-3’ 116
F 5’-CCAGCTCTTGCTTTGCAATC-3’
TnTc NM_000364 R 5’-CATGGAGAAGGACCTGAATGA-3’ 108
F 5’-CGTCTCTCGATCCTGTCTTTG-3’
MEF2C NM_002397 R 5’-CAGTCATTGGCTACCCCAGT-3’ 221
F 5’-GCAGATGGTGGCATGTTATG-3’
Desmin NM_001927 R 5’-GCCTCATCAGGGAATCGTTA-3’ 129
L 5’-AGGCAGCCAACAAGAACAAC-3’
a-Actin NM_005159 R 5’-AGGGGCTGGAAGAGTGTCTCA-3’ 136
L 5’ -GCCCTGGATTTTGAGAATGA-3’
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reaction was carried out using SYBR Green as an indicator
in BioRad iCycler PCR machine. The reaction mixture
consisted of iQ SYBR Supermix, forward and reverse pri-
mers (500 nM each), deionised water and 2 ul cDNA. The
PCR reaction conditions were cycle 1: Step 1 95°C for 3
min, cycle 2 (40x): Step 1 95°C for 10 sec and Step 2 61°C
for 30 sec, cycle 3: Step 1 95°C for 1 min, cycle 4: Step 1
55°C for 1 min and cycle 5: Step 1 60°C for 10 sec. Expres-
sion level of each targeted gene was normalised to
GAPDH. The specificity of the primers and PCR protocol
were confirmed with melting curve analysis and further
verified by 2% agarose gel electrophoresis.
5.6) Statistical Analysis
Data was analysed by using SPSS 15.0 (SPSS Inc., Chi-
cago, IL) and subjected to paired t-test to determine sig-
nificance difference (P < 0.05) of the gene expression
levels between passage P5 and P10. Data were presented
as the mean ± standard error of mean (SEM).
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